<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62040">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01841736</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2013-00831</org_study_id>
    <secondary_id>NCI-2013-00831</secondary_id>
    <secondary_id>ALLIANCE A021202</secondary_id>
    <secondary_id>CALGB-A021202</secondary_id>
    <secondary_id>A021202</secondary_id>
    <secondary_id>A021202</secondary_id>
    <secondary_id>U10CA180821</secondary_id>
    <secondary_id>U10CA031946</secondary_id>
    <nct_id>NCT01841736</nct_id>
  </id_info>
  <brief_title>Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors</brief_title>
  <official_title>Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies how well pazopanib hydrochloride works in treating
      patients with progressive carcinoid tumors. Pazopanib hydrochloride may stop the growth of
      tumor cells by blocking some of the enzymes needed for cell growth.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. For patients with progressive carcinoid tumors, progression-free survival (PFS) (PFS
      defined by central review according to Response Evaluation Criteria in Solid Tumors [RECIST]
      1.1) will be compared between patients randomized to treatment with pazopanib (pazopanib
      hydrochloride) versus placebo.

      SECONDARY OBJECTIVES:

      I. Overall survival will be compared between treatment arms. II. Objective response rate,
      duration of response, and time to treatment failure will be compared between treatment arms.

      III. Progression free survival as assessed by central radiology review and local radiology
      review will be compared overall and within treatment arms.

      IV. PFS at 6 months and 12 months will be estimated within each treatment arm. V. Safety and
      tolerability of treatment with pazopanib/placebo will be evaluated within each treatment
      arm.

      VI. Biochemical response (for chromogranin A, defined as a decrease of 50% or more in plasma
      chromogranin A levels from baseline and for 5-hydroxyindoleacetic acid [5-HIAA], defined as
      a decrease of 50% or more in urinary 5-HIAA levels from baseline) will be compared between
      treatment arms among patients with elevated baseline levels of chromogranin A [CGA] and
      5-HIAA.

      VII. PFS and other indicators of efficacy will be estimated in patients who crossover to
      pazopanib from placebo.

      TERTIARY OBJECTIVES:

      I. Average time to submission of scans to the Imaging Core Laboratory (ICL) and average ICL
      &quot;turn-around&quot; time will be estimated.

      II. Discordance between the local and central radiology review in assessment of progression
      will be estimated.

      III. The rates and quality of radiographic progression (pre-study, on-study, and
      post-progression) will be characterized.

      IV. To assess for differences in quality of life (QOL)-related domains between the two
      treatment groups (pazopanib versus placebo).

      V. To determine if the more brief measures of QOL-related domains provide comparable
      information to that which is provided by the longer assessments (European Organization for
      Research and Treatment of Cancer [EORTC], neuroendocrine tumors [NET]21).

      VI. To provide validation data for the EORTC NET21 module in terms of responsiveness over
      time and differences across arms.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients receive pazopanib hydrochloride orally (PO) once daily (QD) on days 1-28.
      Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

      ARM II: Patients receive placebo PO QD on days 1-28. Courses repeat every 28 days in the
      absence of disease progression or unacceptable toxicity. At the time of progressive disease,
      patients may cross-over to Arm I.

      After completion of study treatment, patients are followed up every 3-6 months for 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From date of patient entry until documented progression of disease or death from any cause, assessed up to 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>PFS will be estimated within treatment arm using the Kaplan-Meier method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR), defined as the percentage of patients with a confirmed complete response (CR) or partial response (PR) per RECIST 1.1 criteria</measure>
    <time_frame>Up to 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The exact binomial confidence interval will be used to estimate ORR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From randomization until death from any cause, assessed up to 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>OS will be estimated by the Kaplan-Meier method within each treatment arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DR) for the subset of patients with a confirmed CR or PR</measure>
    <time_frame>From first documented evidence of CR or PR until first documented disease progression or death from any cause, assessed up to 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>DR will be summarized descriptively using Kaplan-Meier medians and quartiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>From randomization until termination of protocol therapy for any reason including progression of disease, adverse events, and death, assessed up to 5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to second progression for patients who crossover from placebo to active therapy</measure>
    <time_frame>Up to 5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">165</enrollment>
  <condition>Metastatic Gastrointestinal Carcinoid Tumor</condition>
  <condition>Pulmonary Carcinoid Tumor</condition>
  <condition>Recurrent Gastrointestinal Carcinoid Tumor</condition>
  <condition>Recurrent Neuroendocrine Carcinoma of the Skin</condition>
  <condition>Regional Gastrointestinal Carcinoid Tumor</condition>
  <condition>Stage III Neuroendocrine Carcinoma of the Skin</condition>
  <condition>Stage IV Neuroendocrine Carcinoma of the Skin</condition>
  <condition>Thyroid Gland Medullary Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm I (pazopanib hydrochloride)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive placebo PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. At the time of progressive disease, patients may cross-over to Arm I.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pazopanib hydrochloride</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (pazopanib hydrochloride)</arm_group_label>
    <other_name>GW786034B</other_name>
    <other_name>Votrient</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <other_name>PLCB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (pazopanib hydrochloride)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <other_name>quality of life assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (pazopanib hydrochloride)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Low- or intermediate-grade neuroendocrine carcinoma, including the following
             subtypes: carcinoid tumor, low- to intermediate-grade or well- to
             moderately-differentiated neuroendocrine carcinoma or tumor, atypical carcinoid
             tumor; documentation from a primary tumor or metastatic site is sufficient; patients
             with poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine
             carcinoma, adenocarcinoid tumor, or goblet cell carcinoid tumor are not eligible

          -  Locally unresectable or metastatic carcinoid tumors

          -  Patients must have histologic documentation or clinical evidence of a carcinoid tumor
             of primary site (including foregut, midgut, hindgut or other non-pancreatic site);
             tumors of unknown primary site are eligible provided the treating physician does not
             suspect medullary thyroid cancer, pancreatic neuroendocrine tumor, paraganglioma, or
             pheochromocytoma; unknown primary tumors will be classified as small bowel tumors for
             the purpose of stratification; functional (associated with a clinical syndrome) or
             nonfunctional tumors are allowed; target lesions must have shown disease progression
             if therapy included peptide receptor radiotherapy (PRRT) and PRRT must be completed
             at least 8 weeks prior to registration

          -  Radiological evidence for progressive disease (measureable or non-measurable) within
             12 months prior to registration; patients who have received anti-tumor therapy during
             the past 12 months (including octreotide analogs) must have had radiological
             documentation of progression of disease while on or after receiving therapy

          -  No known endobronchial lesions and/or lesions infiltrating major pulmonary vessels
             that increase the risk of pulmonary hemorrhage; patients with lesions infiltrating
             major pulmonary vessels (contiguous tumor and vessels) are excluded; however, the
             presence of a tumor that is touching, but not infiltrating (abutting) the vessels is
             acceptable (computed tomography [CT] with contrast is strongly recommended to
             evaluate such lesions); patients with large protruding endobronchial lesions in the
             main or lobar brochi are excluded; however, endobronchial lesions in the segmented
             bronchi are allowed

          -  Patients must have measurable disease per RECIST 1.1 by computed tomography (CT) scan
             or magnetic resonance imaging (MRI); lesions must be accurately measured in at least
             one dimension (longest diameter to be recorded) as &gt;= 1 cm with CT or MRI (or &gt;= 1.5
             cm for lymph nodes)

          -  No prior treatment with an inhibitor of vascular endothelial growth factor (VEGF) or
             vascular endothelial growth factor receptor (VEGFR)

          -  Prior treatment (somatostatin analogs excepted) must be completed at least 4 weeks
             prior to registration, and any treatment-related toxicities must have improved to =&lt;
             grade 1

          -  Concurrent use of somatostatin analogs (SSTa) is allowed, provided that the patient
             is on a stable dose for at least two months and progressive disease on somatostatin
             analog has been documented; progression on octreotide is required for patients with
             tumors arising in the midgut

          -  Prior treatment with embolization (including bland embolization, chemoembolization,
             and selective internal radiation therapy) or ablative therapies is allowed if
             measurable disease remains outside of the treated area or there is documented disease
             progression in a treated site; there is no limit on the prior number of procedures;
             prior liver-directed or other ablative treatment must be completed at least 8 weeks
             prior to registration

          -  Patients should have completed any major surgery &gt;= 4 weeks prior to registration and
             must have completed any minor surgery &gt;= 2 weeks prior to registration; patients must
             have fully recovered from the procedure

               -  The following are examples of procedures considered to be minor: port placement,
                  laparoscopy, thoracoscopy, bronchoscopy, mediastinoscopy, skin biopsies,
                  incisional biopsies, imaging-guided biopsy for diagnostic purposes, and dental
                  extraction procedures

               -  Insertion of a vascular access device, thoracentesis, paracentesis, and
                  endoscopic ultrasonographic procedures are not considered to be major or minor
                  surgeries

          -  No concurrent condition resulting in immune compromise, including chronic treatment
             with corticosteroids or other immunosuppressive agents

          -  No clinical evidence of central nervous system (CNS) metastases (including
             carcinomatous meningitis) at baseline, with the exception of those patients who have
             previously-treated CNS metastases (surgery +/- radiotherapy, radiosurgery, or gamma
             knife) and who meet both of the following criteria: a) are asymptomatic and b) had no
             requirement for steroids or enzyme-inducing anticonvulsants within 6 months prior to
             registration

          -  No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal
             abscess within 28 days prior to registration

          -  No clinically significant gastrointestinal abnormalities that may increase the risk
             for gastrointestinal bleeding within 28 days prior to registration including, but not
             limited to:

               -  Active peptic ulcer

               -  Known endoluminal metastatic lesion(s) with history of bleeding

               -  Inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease), or other
                  gastrointestinal conditions with increased risk of perforation

          -  No history of serious (i.e., requiring active medical therapy with medication or
             medical device under the supervision of a physician) non-healing wound, ulcer,
             trauma, or bone fracture within 28 days prior to study entry

          -  Patients with a history of hypertension must have blood pressure that is adequately
             controlled on antihypertensives; (&lt; 140/90 mmHg)

          -  No symptomatic congestive heart failure (New York Heart Association class II, III, or
             IV) within 6 months prior to registration

          -  No arterial thrombotic events within 6 months of registration, including transient
             ischemic attack (TIA), cerebrovascular accident (CVA), peripheral arterial thrombus,
             unstable angina or angina requiring surgical or medical intervention in 6 months
             prior to registration, or myocardial infarction (MI); patients with clinically
             significant peripheral artery disease (i.e., claudication on less than one block) are
             ineligible; patients who have experienced a deep venous thrombosis or pulmonary
             embolus within 6 months prior to registration must be on stable therapeutic
             anticoagulation for at least 6 weeks prior to enrollment of this study

          -  Patients on therapeutic anticoagulation with low molecular weight heparins,
             fondaparinux, or warfarin are eligible, provided that they are on a stable dose of
             anticoagulants; patients who are currently receiving antiplatelet therapy of
             prasugrel or clopidogrel or antiaggregation agents (e.g., eptifibatide, epoprostenol,
             dipyridamole) or low doses of acetylsalicylic acid (up to 100 mg daily) are also
             eligible

          -  No ongoing cardiac dysrhythmias, atrial fibrillation, or prolongation of corrected
             QTc interval to &gt; 480 msec

          -  No evidence of active bleeding, bleeding diathesis, or hemoptysis (&gt;= 1/2 teaspoon of
             red blood) within 8 weeks prior to registration

          -  No currently unstable angina and/or uncontrolled cardiac arrhythmias

          -  Patients with symptomatic peripheral vascular disease are ineligible

          -  Ejection fraction on echocardiogram (Echo) or multi gated acquisition scan (MUGA) &gt;
             50%

          -  Chronic concomitant treatment with strong inhibitors of cytochrome P450, family 3,
             subfamily A, polypeptide 4 (CYP3A4) is not allowed on this trial; patients on strong
             CYP3A4 inhibitors must discontinue the drug 14 days prior to the start of study
             treatment

          -  Women must not be pregnant or nursing; women of child bearing potential must have a
             negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent
             units of human chorionic gonadotropin [HCG]) within 72 hours prior to registration;
             women of child-bearing potential include any female who has experienced menarche and
             who has not undergone surgical sterilization (hysterectomy, bilateral tubal ligation
             or bilateral oophorectomy) or is not postmenopausal (defined as amenorrhea &gt;= 12
             consecutive months; or women on hormone replacement therapy [HRT] with documented
             serum follicle stimulating hormone [FSH] level &gt; 35 mIU/mL)

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          -  Granulocytes &gt;= 1,500/mcL

          -  Platelets &gt;= 100,000/mcL

          -  International normalized ratio (INR) =&lt; 1.2 X upper limit of normal (ULN); only
             required for patients receiving anticoagulant therapy; patients are eligible if their
             INR is stable and within the recommended range for the desired level of
             anticoagulation

          -  QTc =&lt; 480 msecs

          -  Thyroid stimulating hormone (TSH) within normal limits (WNL); medications for thyroid
             dysfunction are allowed as long as TSH is normal at registration

          -  Bilirubin =&lt; 1.5 x ULN

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) &amp;
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =&lt; 2.5
             x ULN; concomitant elevations in bilirubin and AST/ALT above 1.0 X ULN are NOT
             permitted; also, if liver metastases are present, AST &amp; ALT =&lt; 5 x ULN is allowed

          -  Serum creatinine =&lt; 1.5 x ULN

          -  Urine protein to creatinine (UPC) ratio &lt; 1, or, 24-hour urine protein &lt; 1g; if UPC
             &gt;= 1, then a 24-hour urine protein must be assessed; patients must have a 24-hour
             urine protein value &lt; 1 g to be eligible; use of urine dipstick for renal function
             assessment is not acceptable
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emily Bergsland</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer and Leukemia Group B</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward M. Wolin</last_name>
      <phone>310-423-8965</phone>
    </contact>
    <investigator>
      <last_name>Edward M. Wolin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Southern California/Norris Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Syma Iqbal</last_name>
      <phone>323-865-0451</phone>
    </contact>
    <investigator>
      <last_name>Syma Iqbal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF-Mount Zion</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Front Range Cancer Specialists</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80528</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Poudre Valley Hospital</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80524</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regina J. Brown</last_name>
      <phone>970-495-8226</phone>
    </contact>
    <investigator>
      <last_name>Regina J. Brown</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan R. Strosberg</last_name>
      <phone>800-456-7121</phone>
      <email>canceranswers@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Jonathan R. Strosberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pali Momi Medical Center</name>
      <address>
        <city>Aiea</city>
        <state>Hawaii</state>
        <zip>96701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey L. Berenberg</last_name>
      <phone>808-586-2979</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey L. Berenberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncare Hawaii Inc-Pali Momi</name>
      <address>
        <city>Aiea</city>
        <state>Hawaii</state>
        <zip>96701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey L. Berenberg</last_name>
      <phone>808-586-2979</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey L. Berenberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kapiolani Medical Center for Women and Children</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96826</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey L. Berenberg</last_name>
      <phone>808-586-2979</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey L. Berenberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OnCare Hawaii-Liliha</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817-3169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey L. Berenberg</last_name>
      <phone>808-586-2979</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey L. Berenberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncare Hawaii Inc-POB II</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey L. Berenberg</last_name>
      <phone>808-586-2979</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey L. Berenberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Hawaii</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey L. Berenberg</last_name>
      <phone>808-586-2979</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey L. Berenberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen's Medical Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey L. Berenberg</last_name>
      <phone>808-586-2979</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey L. Berenberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Straub Clinic and Hospital</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey L. Berenberg</last_name>
      <phone>808-586-2979</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey L. Berenberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Castle Medical Center</name>
      <address>
        <city>Kailua</city>
        <state>Hawaii</state>
        <zip>96734</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey L. Berenberg</last_name>
      <phone>808-586-2979</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey L. Berenberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wilcox Memorial Hospital and Kauai Medical Clinic</name>
      <address>
        <city>Lihue</city>
        <state>Hawaii</state>
        <zip>96766</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey L. Berenberg</last_name>
      <phone>808-586-2979</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey L. Berenberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Al B. Benson</last_name>
      <phone>312-695-1301</phone>
      <email>cancer@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Al B. Benson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manish R. Sharma</last_name>
      <phone>773-834-7424</phone>
    </contact>
    <investigator>
      <last_name>Manish R. Sharma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janelle M. Meyer</last_name>
      <phone>708-226-4357</phone>
    </contact>
    <investigator>
      <last_name>Janelle M. Meyer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Michiana Hematology Oncology PC-Mishawaka</name>
      <address>
        <city>Mishawaka</city>
        <state>Indiana</state>
        <zip>46545-1470</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin T. Zon</last_name>
      <phone>574-234-5123</phone>
    </contact>
    <investigator>
      <last_name>Robin T. Zon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Sharma</last_name>
      <phone>800-237-1225</phone>
    </contact>
    <investigator>
      <last_name>Nancy Sharma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center Jefferson</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jyotsna Fuloria</last_name>
      <phone>888-562-4763</phone>
    </contact>
    <investigator>
      <last_name>Jyotsna Fuloria</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Mercy Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106-0995</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tareq Al Baghdadi</last_name>
      <phone>734-712-3456</phone>
    </contact>
    <investigator>
      <last_name>Tareq Al Baghdadi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Health Saint Mary's</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilbert D. Padula</last_name>
      <phone>616-685-5225</phone>
    </contact>
    <investigator>
      <last_name>Gilbert D. Padula</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spectrum Health at Butterworth Campus</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilbert D. Padula</last_name>
      <phone>616-685-5225</phone>
    </contact>
    <investigator>
      <last_name>Gilbert D. Padula</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Mercy Port Huron</name>
      <address>
        <city>Port Huron</city>
        <state>Michigan</state>
        <zip>48060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tareq Al Baghdadi</last_name>
      <phone>734-712-3456</phone>
    </contact>
    <investigator>
      <last_name>Tareq Al Baghdadi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Munson Medical Center</name>
      <address>
        <city>Traverse City</city>
        <state>Michigan</state>
        <zip>49684</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilbert D. Padula</last_name>
      <phone>616-685-5225</phone>
    </contact>
    <investigator>
      <last_name>Gilbert D. Padula</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Essentia Health Duluth Clinic CCOP</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bret E. Friday</last_name>
      <phone>888-203-7267</phone>
    </contact>
    <investigator>
      <last_name>Bret E. Friday</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unity Hospital</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel M. Anderson</last_name>
      <phone>952-993-1517</phone>
      <email>MMCCOP@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Daniel M. Anderson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint John's Mercy Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay W. Carlson</last_name>
      <phone>800-821-7532</phone>
      <email>sherrijr@iora.org</email>
    </contact>
    <investigator>
      <last_name>Jay W. Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Louis Cancer and Breast Institute-South City</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay W. Carlson</last_name>
      <phone>800-821-7532</phone>
      <email>sherrijr@iora.org</email>
    </contact>
    <investigator>
      <last_name>Jay W. Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin R. Tan</last_name>
      <phone>800-600-3606</phone>
      <email>info@siteman.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Benjamin R. Tan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J. M. Pipas</last_name>
      <phone>800-639-6918</phone>
      <email>cancer.research.nurse@dartmouth.edu</email>
    </contact>
    <investigator>
      <last_name>J. M. Pipas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center-Weiler Division</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven K. Libutti</last_name>
      <phone>718-904-2730</phone>
      <email>aecc@aecom.yu.edu</email>
    </contact>
    <investigator>
      <last_name>Steven K. Libutti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467-2490</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven K. Libutti</last_name>
      <phone>718-904-2730</phone>
      <email>aecc@aecom.yu.edu</email>
    </contact>
    <investigator>
      <last_name>Steven K. Libutti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan W. Friedberg</last_name>
      <phone>585-275-5830</phone>
    </contact>
    <investigator>
      <last_name>Jonathan W. Friedberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen A. Bernard</last_name>
      <phone>877-668-0683</phone>
      <email>cancerclinicaltrials@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Stephen A. Bernard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Margaret R Pardee Memorial Hospital</name>
      <address>
        <city>Hendersonville</city>
        <state>North Carolina</state>
        <zip>28791</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James E. Radford</last_name>
      <phone>828-696-4716</phone>
    </contact>
    <investigator>
      <last_name>James E. Radford</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kinston Medical Specialists PA</name>
      <address>
        <city>Kinston</city>
        <state>North Carolina</state>
        <zip>28501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter R. Watson</last_name>
      <phone>252-559-2200</phone>
    </contact>
    <investigator>
      <last_name>Peter R. Watson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer R. Eads</last_name>
      <phone>800-641-2422</phone>
    </contact>
    <investigator>
      <last_name>Jennifer R. Eads</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manisha H. Shah</last_name>
      <phone>866-627-7616</phone>
      <email>osu@emergingmed.com</email>
    </contact>
    <investigator>
      <last_name>Manisha H. Shah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Vincent Mercy Medical Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Toledo</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rex B. Mowat</last_name>
      <phone>517-265-0116</phone>
    </contact>
    <investigator>
      <last_name>Rex B. Mowat</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Kurkjian</last_name>
      <phone>405-271-4272</phone>
      <email>julie-traylor@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Carla Kurkjian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tulsa Cancer Institute</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Kurkjian</last_name>
      <phone>405-271-4272</phone>
      <email>julie-traylor@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Carla Kurkjian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Milwaukie Hospital</name>
      <address>
        <city>Milwaukie</city>
        <state>Oregon</state>
        <zip>97222</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison K. Conlin</last_name>
      <phone>503-215-6412</phone>
    </contact>
    <investigator>
      <last_name>Alison K. Conlin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Newberg Medical Center</name>
      <address>
        <city>Newberg</city>
        <state>Oregon</state>
        <zip>97132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison K. Conlin</last_name>
      <phone>503-215-6412</phone>
    </contact>
    <investigator>
      <last_name>Alison K. Conlin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Willamette Falls Medical Center</name>
      <address>
        <city>Oregon City</city>
        <state>Oregon</state>
        <zip>97045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison K. Conlin</last_name>
      <phone>503-215-6412</phone>
    </contact>
    <investigator>
      <last_name>Alison K. Conlin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison K. Conlin</last_name>
      <phone>503-215-6412</phone>
    </contact>
    <investigator>
      <last_name>Alison K. Conlin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Luke's University Hospital-Bethlehem Campus</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darius C. Desai</last_name>
      <phone>610-954-3582</phone>
      <email>infolink@slhn.org</email>
    </contact>
    <investigator>
      <last_name>Darius C. Desai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Health System Cancer Institute-Faris</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey K. Giguere</last_name>
      <phone>864-241-6251</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey K. Giguere</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Health System Cancer Institute/Greenville CCOP</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey K. Giguere</last_name>
      <phone>864-241-6251</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey K. Giguere</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Health System Cancer Institute-Seneca</name>
      <address>
        <city>Seneca</city>
        <state>South Carolina</state>
        <zip>29672</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey K. Giguere</last_name>
      <phone>864-241-6251</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey K. Giguere</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Health System Cancer Institute-Spartanburg</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey K. Giguere</last_name>
      <phone>864-241-6251</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey K. Giguere</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noelle K. LoConte</last_name>
      <phone>877-405-6866</phone>
    </contact>
    <investigator>
      <last_name>Noelle K. LoConte</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Joseph's Hospital</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rezwan Islam</last_name>
      <phone>715-393-1400</phone>
    </contact>
    <investigator>
      <last_name>Rezwan Islam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BCCA-Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hagen F. Kennecke</last_name>
      <phone>888-939-3333</phone>
    </contact>
    <investigator>
      <last_name>Hagen F. Kennecke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Vitalite Health Network - Dr Leon Richard Oncology Centre</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 8X3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas G. Finn</last_name>
      <phone>506-862-4005</phone>
    </contact>
    <investigator>
      <last_name>Nicholas G. Finn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ottawa Health Research Institute-General Division</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy R. Asmis</last_name>
      <phone>613-761-4395</phone>
      <email>info@ohri.ca</email>
    </contact>
    <investigator>
      <last_name>Timothy R. Asmis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>April 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoid Tumor</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Merkel Cell</mesh_term>
    <mesh_term>Carcinoma, Medullary</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Neuroendocrine</mesh_term>
    <mesh_term>Malignant Carcinoid Syndrome</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Basal Cell</mesh_term>
    <mesh_term>Carcinoma, Basosquamous</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
